WHO ICTRP trial
The effects of galantamine on brain network topology in patients with…
JPRN-jRCTs031180337 · Japan Primary Registries Network (JPRN) · Not Recruiting
Key facts
| Trial ID | JPRN-jRCTs031180337 |
|---|---|
| Public title | The effects of galantamine on brain network topology in patients with Alzheimer's disease |
| Scientific title | The effects of galantamine administration on brain network topology in patients with Alzheimer's disease (AD): A possible new biomarker for pharmacotherapy of AD |
| Primary sponsor | Hanakawa Takashi |
| Secondary sponsors | Janssen Pharmaceutical K.K. |
| Registry | Japan Primary Registries Network (JPRN) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Conditions | mild to moderate Alzhiemer's disease |
| Interventions | Administration of galantamine (4mg) (One time) |
| Registration date | Mar 18, 2019 |
| Target size | 20 |
| Secondary IDs | UMIN000018749 |
| Registry page | jrct.niph.go.jp |
At a glance
- Yes Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: